LGVN
Longeveron Inc.
$0.7830
+1.56%
$24.7M
No data for this timeframe.
Vol
Market Cap$24.7M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders13 funds
Inst. Value$1.0M
Inst. Activity2 buys / 0 sells
Reddit Sentiment63° Warm
SEC Reports7
Press Releases3
Recent Activity
Jun 9, 2026
other
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
Longeveron (LGVN) granted Small or Medium-sized Enterprise (SME) status by the European Medicines Ag
Jun 5, 2026
SEC
CFO Lisa Locklear is stepping down effective July 10, 2026, with controller Marie Washburn expected to be elevated into
8-K — Impact 4/10
May 13, 2026
SEC
Longeveron reported Q1 2026 results in line with consensus: EPS -$0.19 matched Street estimates and revenue of $398K was
8-K — Impact 3/10
May 8, 2026
SEC
Longeveron disclosed that the FDA rejected the primary endpoint (RVEF) of its Phase 2b ELPIS II trial for HLHS, and the
8-K — Impact 7/10
May 1, 2026
Insider
Locklear Lisa was granted 250,000 shares
Chief Financial Officer
May 1, 2026
Insider
Lehr Paul T was granted 250,000 shares
General Counsel, Secretary
May 1, 2026
Insider
Agafonova Nataliya was granted 250,000 shares
Chief Medical Officer
Inst.
BlackRock, Inc. — DOUBLED
224,198 shares ($233.2K)
Price Targets
$7.15
+813.6% upside
Strong Buy
Current $0.7826
Low $3.00
Median $8.00
High $10.45
3 analysts
$3.00
$10.45
Analyst Ratings
2Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Maxim Group | DOWNGRADE | Buy → Hold |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.19 ▼ -14.0% | $-0.21 — $-0.18 | 42% YoY | 3 |
| Next Q | $-0.15 | $-0.19 — $-0.10 | 62% YoY | 3 |
| Current FY | $-0.68 ▼ -70.0% | $-0.74 — $-0.61 | 47% YoY | 3 |
| Next FY | $-0.46 ▲ +15.3% | $-0.70 — $-0.30 | 32% YoY | 4 |
Latest Reports
NEUTRAL
8-K
4/10
CFO Lisa Locklear is stepping down effective July 10, 2026, with controller Marie Washburn expected to be elevated into
Jun 5, 2026
NEUTRAL
Press
4/10
Longeveron issued a CEO letter detailing a strategic repositioning toward a capital-light, partnership-focused model, wi
May 20, 2026
NEUTRAL
8-K
3/10
Longeveron reported Q1 2026 results in line with consensus: EPS -$0.19 matched Street estimates and revenue of $398K was
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $563.7K | — |
| BlackRock, Inc. | $233.2K | DOUBLED |
| Beacon Pointe Advisors, LLC | $104.0K | — |
| STATE STREET CORP | $47.2K | DOUBLED |
| VANGUARD FIDUCIARY TRUST CO | $40.3K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | Locklear Lisa | A | $0.00 |
| May 1, 2026 | Lehr Paul | A | $0.00 |
| May 1, 2026 | Agafonova Nataliya | A | $0.00 |
| May 1, 2026 | Blass Devin | A | $0.00 |
| May 1, 2026 | Willard Stephen | A | $0.00 |
Reddit Sentiment
63°
Warm
Bearish
Neutral
Bullish
13 institutional holders with $1.0M total value (1,107,471 shares) as of 2026-Q1. Top holders: VANGUARD, BlackRock,, Beacon. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 542,032 | $563.7K | 54.8% | — |
| 2 | BlackRock, Inc. | 224,198 | $233.2K | 22.7% | DOUBLED +2138.4% |
| 3 | Beacon Pointe Advisors, LLC | 100,000 | $104.0K | 10.1% | — |
| 4 | STATE STREET CORP | 45,380 | $47.2K | 4.6% | DOUBLED +198.9% |
| 5 | VANGUARD FIDUCIARY TRUST CO | 38,715 | $40.3K | 3.9% | — |
| 6 | COMMONWEALTH EQUITY SERVICES, LLC | 25,155 | $26.2K | 2.5% | ADD +57.7% |
| 7 | Lido Advisors, LLC | 11,235 | $11.7K | 1.1% | — |
| 8 | FMR LLC | 752 | $782.00 | 0.1% | NEAR_EXIT -99.7% |
| 9 | MORGAN STANLEY | 680 | $707.00 | 0.1% | ADD +32.1% |
| 10 | JONES FINANCIAL COMPANIES LLLP | 300 | $276.00 | 0.0% | — |
| 11 | Allworth Financial LP | 130 | $136.00 | 0.0% | — |
| 12 | HRT FINANCIAL LP | 118,891 | $123.00 | 0.0% | DOUBLED +891.7% |
| 13 | CWM, LLC | 3 | $3.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 10,016 | 224,198 | +2138.4% | $233.2K | 2026-Q1 |
| HRT FINANCIAL LP | DOUBLED | 11,989 | 118,891 | +891.7% | $123.00 | 2026-Q1 |
| HRT FINANCIAL LP | TRIM | 17,257 | 11,989 | -30.5% | $6.00 | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 144,272 | 505,572 | +250.4% | $379.2K | 2025-Q3 |
| UBS Group AG | ADD | 55,264 | 84,135 | +52.2% | $109.4K | 2025-Q2 |
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | 15,955 | 25,155 | +57.7% | $33.00 | 2025-Q2 |
| PNC FINANCIAL SERVICES GROUP, INC. | NEAR_EXIT | 74 | 17 | -77.0% | $22.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,013 | 55,264 | +5355.5% | $85.7K | 2025-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | NEAR_EXIT | 297 | 74 | -75.1% | $115.00 | 2025-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | 12,455 | 15,955 | +28.1% | $25.00 | 2025-Q1 |
| VANGUARD GROUP INC | DOUBLED | 44,984 | 144,272 | +220.7% | $249.6K | 2024-Q4 |
| STATE STREET CORP | DOUBLED | 15,180 | 45,380 | +198.9% | $78.5K | 2024-Q4 |
| UBS Group AG | ADD | 617 | 1,013 | +64.2% | $1.8K | 2024-Q4 |
| FMR LLC | NEAR_EXIT | 326 | 1 | -99.7% | $2.00 | 2024-Q4 |
| MORGAN STANLEY | ADD | 1,409 | 1,861 | +32.1% | $3.6K | 2024-Q3 |
| FMR LLC | DOUBLED | 1 | 326 | +32500.0% | $632.00 | 2024-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 1,682 | 105 | -93.8% | $204.00 | 2024-Q3 |
5 unique insiders with 13 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | Locklear Lisa | Chief Financial Officer | AWARD | 250,000 | — | — |
| May 1, 2026 | Lehr Paul T | General Counsel, Secretary | AWARD | 250,000 | — | — |
| May 1, 2026 | Agafonova Nataliya | Chief Medical Officer | AWARD | 250,000 | — | — |
| May 1, 2026 | Blass Devin | CTO & SVP of CMC | AWARD | 250,000 | — | — |
| May 1, 2026 | Willard Stephen H | Chief Executive Officer | AWARD | 500,000 | — | — |
| Apr 1, 2026 | Agafonova Nataliya | Chief Medical Officer | TAX W/H | 13,145 | $1.12 | $14.7K |
| Apr 1, 2026 | Willard Stephen H | Chief Executive Officer | TAX W/H | 4,740 | $1.12 | $5.3K |
| Apr 1, 2026 | Locklear Lisa | Chief Financial Officer | TAX W/H | 13,145 | $1.12 | $14.7K |
| Apr 1, 2026 | Blass Devin | CTO & SVP of CMC | TAX W/H | 8,633 | $1.12 | $9.7K |
| Apr 1, 2026 | Lehr Paul T | General Counsel, Secretary | TAX W/H | 5,611 | $1.12 | $6.3K |
| Mar 2, 2026 | Willard Stephen H | Chief Executive Officer | AWARD | 200,000 | — | — |
| Mar 2, 2026 | Willard Stephen H | Chief Executive Officer | TAX W/H | 105,533 | $0.5450 | $57.5K |
| Mar 2, 2026 | Willard Stephen H | Chief Executive Officer | AWARD | 200,000 | — | — |
7 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 0 mixed, 3 neutral. Avg impact: 5.1/10.
NEUTRAL
8-K
4/10
CFO Lisa Locklear is stepping down effective July 10, 2026, with controller Marie Washburn expected
Jun 5, 2026
NEUTRAL
8-K
3/10
Longeveron reported Q1 2026 results in line with consensus: EPS -$0.19 matched Street estimates and
May 13, 2026
BEARISH
8-K
7/10
Longeveron disclosed that the FDA rejected the primary endpoint (RVEF) of its Phase 2b ELPIS II tria
May 8, 2026
BEARISH
EFFECT
6/10
Longeveron Inc. (LGVN) has announced the effectiveness of its S-1 registration, allowing 30.9 millio
Apr 20, 2026
NEUTRAL
8-K
3/10
Longeveron Inc. restored executive and board compensation after a temporary reduction and approved r
Apr 10, 2026
BEARISH
S-1
6/10
Longeveron Inc. (LGVN) is registering 30.9 million shares for resale by selling stockholders, includ
Apr 10, 2026
BEARISH
8-K
7/10
Longeveron Inc. filed an 8-K disclosing that board member and audit committee financial expert Richa
Mar 9, 2026
NEUTRAL
4/10
Longeveron issued a CEO letter detailing a strategic repositioning toward a capital-light, partnersh
May 20, 2026
BEARISH
7/10
Longeveron reported a 50% year-over-year revenue decline for 2025, driven by lower clinical trial an
Mar 17, 2026
MIXED
6/10
Longeveron (LGVN) closed the first tranche of a $30 million private placement, raising $15 million u
Mar 11, 2026
Current analyst consensus: Buy (78% buy). Based on 9 analysts: 2 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.15 mean target
+813.6% upside
Strong Buy (3.00)
$3.00 Low
$10.45 High
| Metric | Value |
|---|---|
| Current Price | $0.7826 |
| Target Low | $3.00 |
| Target Mean | $7.15 |
| Target Median | $8.00 |
| Target High | $10.45 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.19 | $-0.21 | $-0.18 | 42.4% | -14.0% | 0↑ 1↓ | $0.0B | 3.2% | 3 |
| Next Q 2026-09-30 |
$-0.15 | $-0.19 | $-0.10 | 61.5% | +0.0% | 0↑ 1↓ | $0.0B | 183.8% | 3 |
| Current FY 2026-12-31 |
$-0.68 | $-0.74 | $-0.61 | 47.3% | -70.0% | 0↑ 1↓ | $0.0B | 24.6% | 3 |
| Next FY 2027-12-31 |
$-0.46 | $-0.70 | $-0.30 | 32.3% | +15.3% | 1↑ 1↓ | $0.0B | 336.9% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.190 | |
| 7d ago | $-0.180 | -0.010 |
| 30d ago | $-0.167 | -0.023 |
| 60d ago | $-0.217 | +0.027 |
| 90d ago | $-0.215 | +0.025 |
2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Maxim Group | DOWNGRADE | Buy | Hold |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
63°
Warm
Bearish
Neutral
Bullish
4 mentions
2 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 9, 2026
other
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
Longeveron (LGVN) granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA).
Jun 4, 2026
other
Longeveron to Present at BIO International Convention 2026
Longeveron will present at BIO 2026. CEO, CFO & BD will host meetings to explore partnership opportunities for its 4 stem cell therapy developmet prog
May 20, 2026
activist
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron CEO issues 2026 Letter to Stockholders.
May 13, 2026
earnings_calendar
LGVN Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
other
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Longeveron announces Data Monitoring Committee for Phase 2b clinical trial in HLHS completed a risk-benefit assessment and recommended continuation.
May 8, 2026
other
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron announced that a constructive Type C meeting with the U.S. FDA was held to discuss the ongoing development of laromestrocel in HLHS.
May 8, 2026
earnings_calendar
LGVN Q1 2026 Earnings Scheduled — 2026-05-08
May 5, 2026
earnings
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
Longeveron will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026.
Apr 13, 2026
Clinical Trial
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 13, 2026
clinical_trial_readout
T-90d Trial Readout: Lomecel-B medicinal signaling cells (Phase 2)
Trial: Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
Sponsor: Longeveron Inc
Apr 8, 2026
other
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MS
Apr 6, 2026
clinical_trial_readout
T-90d Trial Readout: Lomecel-B medicinal signaling cells (Phase 2)
Trial: Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
Sponsor: Longeveron Inc
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: Lomecel-B medicinal signaling cells (Phase 2)
Trial: Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
Sponsor: Longeveron Inc
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: Lomecel-B medicinal signaling cells (Phase 2)
Trial: Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
Sponsor: Longeveron Inc
Apr 1, 2026
short_volume
Short Volume: LGVN — 57.0% short (0.5M / 0.9M)
Short: 524,597 | Exempt: 3,004 | TRF Vol: 920,815 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
Mar 17, 2026
earnings
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3